Recent studies have suggested that successful antitumor responses consisted of a combination of T cell-mediated and non-T cell-mediated mechanisms. We have used transplantable mouse renal and autochthonous mammary carcinoma models to demonstrate that the systemic administration of the combination of IL-2 + IL-12 yields enhanced antitumor effects against even well-established metastatic cancers. Specifically, the systemic administration of IL-12/pulse IL-2 induces complete regression of established renal cancer by a mechanism that is dependent on CD8+ T cells and the production of interferon-gamma (IFNg). Histologic sections from mice treated with IL-12/IL-2 reveal large bands of necrosis and a clear reduction in vascularity that is macroscopically evident via a novel latex infusion method. The IL-12/IL-2 combination potently enhances, in an IFNg- dependent manner, the expression of genes encoding the antiangiogenic chemokines IP-10 and MIG but not the genes that code for such proangiogenic mediators (i.e. VEGF, TGFbeta, angiogenin, FLT-1, or FLK-1), as well as Fas and FasL within the local tumor site. The induction of Fas and FasL in the tumor bed correspond to an increase in apoptosis in the tumor site. Further, we have also observed that IL- 12/pulse IL-2 can induce complete regression of established tumor in a transgenic model of spontaneous mammary carcinoma. Administration of IL- 12/IL-2 enhances expression of genes encoding Fas and FasL, as well as the antiangiogenic chemokines IP-10 and MIG within established tumors. Treatment of mice bearing established mammary carcinoma with IL-12/IL-2 also prevents the emergence of new tumors compared to the progressive multifocal mammary carcinomas that develop in control mice. Administration of Administration of IL-12/IL-2 to juvenile transgenic mice delays the progressive hyperplasia, atypia and overt carcinoma that emerges in control mice, and markedly enhances local T-cell infiltration, Fas/FasL gene expression and apoptosis in the mammary sites of treated mice. These results suggest that successful biological therapy may depend on a complex combination of immune-mediated and immune- dependent(i.e. antiangiogenic) events. Our present studies are focused on determining the relative contributions of these processes to antitumor responses induced by IL-12/IL-2, and the molecular mechanisms that regulate them. In addition, we are pursuing appropriate collaborative relationships to perform non-human primate toxicology of the IL-12/IL-2 combination, as a precursor to a Phase I clinical trial of this cytokine combination.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC009262-16
Application #
6100953
Study Section
Special Emphasis Panel (LEI)
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kudo-Saito, Chie; Wansley, Elizabeth K; Gruys, M Eilene et al. (2007) Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res 13:1936-46
Kummar, Shivaani; Kinders, Robert; Rubinstein, Larry et al. (2007) Compressing drug development timelines in oncology using phase '0'trials. Nat Rev Cancer 7:131-9
Peter, Marcus E; Budd, Ralph C; Desbarats, Julie et al. (2007) The CD95 receptor: apoptosis revisited. Cell 129:447-50
Weiss, Jonathan M; Subleski, Jeff J; Wigginton, Jon M et al. (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7:1705-21
Yazawa, H; Murakami, T; Li, H-M et al. (2006) Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. Cancer Gene Ther 13:993-1001
Shorts, Lynnette; Weiss, Jonathan M; Lee, Jong-Keuk et al. (2006) Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 176:6543-52
Ortaldo, John R; Winkler-Pickett, Robin T; Bere Jr, Earl W et al. (2005) In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 175:693-9
Welniak, Lisbeth A; Shorts, Lynnette; Subleski, Jeff et al. (2004) Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant 10:534-9
Ortaldo, John R; Young, Howard A; Winkler-Pickett, Robin T et al. (2004) Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 172:943-53
Hussain, S Perwez; Trivers, Glennwood E; Hofseth, Lorne J et al. (2004) Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 64:6849-53

Showing the most recent 10 out of 18 publications